Physician profile
Terry Lynn Smith
NPI 1710952585
$10,155.00
in general payments reported to CMS, 2019-2025
41 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,668 · 2022: $1,580 · 2023: $1,610 · 2024: $2,993 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,894 · Education: $12.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,894.38 |
| Education | $12.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,851.50 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,842.17 | 2021-2025 | |
| Novo Nordisk INC | $851.73 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $661.22 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $493.54 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.59 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $417.07 | 2021-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $336.68 | 2023-2025 | Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $313.74 | 2022-2025 | |
| Amgen INC. | $274.93 | 2021-2024 | Repatha, Otezla |
| Indivior INC. | $265.44 | 2022-2025 | Sublocade |
| Axsome Therapeutics, INC. | $258.83 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $257.87 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $210.30 | 2023-2025 | Nuzyra, Xhance |
| Vanda Pharmaceuticals INC. | $205.83 | 2025 | Fanapt, Hetlioz |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.